Related Experiment Video
Updated: Nov 8, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?
Lawrence D True1, Delphine L Chen2
1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington. ltrue@uw.edu dlchen7@uw.edu.
Abstract:
Current techniques for imaging prostate cancer (CT, MRI, and PET agents 18F-fluorodeoxyglucose, 11C-choline, 11C-acetate, and 18F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent 68Ga-PSMA-11 has recently been approved by the FDA. We comment on the performance of novel PSMA agent 18F-DCFPyL-PET/CT.See related article by Morris et al., p. 3674.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
10:20Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
Published on: October 26, 2018
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET